Natural History of Neurological Abnormalities in Cerebrotendinous Xanthomatosis

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2018 Feb 28

PMID 29484516

Citations 17

Authors

Janice C Wong

Kailey Walsh

Douglas Hayden

Florian S Eichler

Affiliations

Soon will be listed here.

Abstract

Objectives: Cerebrotendinous xanthomatosis (CTX) is a rare inherited neurodegenerative disorder in bile acid synthesis. The natural history of neurological abnormalities in CTX is not well understood. The object of this study was to determine neurological progression in CTX.

Methods: A literature search on PubMed for "cerebrotendinous xanthomatosis" yielded 91 publications that reported cases of CTX patients. Two independent reviewers abstracted information about the presence and age of onset of neurological abnormalities in published CTX cases. For each neurological abnormality, we estimated the probability of its onset at any given age using cumulative incidence function analysis. We also present our own case series, in which five CTX patients were evaluated.

Results: The literature search yielded 194 CTX cases (ages ranging from newborn to 67 years old). The most common neurological abnormalities were corticospinal tract abnormalities including weakness, hyperreflexia, spasticity, Babinski sign (59.8%), ataxia (58.8%), cognitive decline (46.4%), and gait difficulty (38.1%); 68 (35.0%) had baseline cognitive problems. Cumulative incidence function analysis revealed that ataxia, gait difficulties, and corticospinal tract abnormalities developed throughout life, while cognitive decline tended to develop later in life. Of the less common neurological abnormalities, seizures, psychiatric changes and speech changes developed throughout life, while parkinsonism and sensory changes tended to develop later in life. Our case series corroborated this temporal pattern of neurological abnormalities.

Conclusion: We provide estimates for the neurological progression of CTX, categorizing neurological abnormalities according to time and probability of development. Our approach may be applicable to other rare disorders.

Citing Articles

Cerebrotendinous Xanthomatosis patients with late diagnosed in single orthopedic clinic: two novel variants in the CYP27A1 gene.

Koroglu M, Karakaplan M, Gunduz E, Kesriklioglu B, Ergen E, Aslanturk O Orphanet J Rare Dis. 2024; 19(1):53.

PMID: 38336741 PMC: 10858589. DOI: 10.1186/s13023-024-03082-4.

Membrane Lipids in Ultra-High-Risk Patients: Potential Predictive Biomarkers of Conversion to Psychosis.

Frajerman A, Chaumette B, Farabos D, Despres G, Simonard C, Lamaziere A Nutrients. 2023; 15(9).

PMID: 37432345 PMC: 10181001. DOI: 10.3390/nu15092215.

Roles of bile acids signaling in neuromodulation under physiological and pathological conditions.

Xing C, Huang X, Wang D, Yu D, Hou S, Cui H Cell Biosci. 2023; 13(1):106.

PMID: 37308953 PMC: 10258966. DOI: 10.1186/s13578-023-01053-z.

A Rare Case of Cerebrotendinous Xanthomatosis Associated With a Mutation on COG8 Gene.

Ghoshouni H, Sarmadian R, Irilouzadian R, Nejad Biglari H, Gilani A J Investig Med High Impact Case Rep. 2023; 11:23247096231168109.

PMID: 37083278 PMC: 10126670. DOI: 10.1177/23247096231168109.

Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis.

Pramparo T, Steiner R, Rodems S, Jenkinson C Orphanet J Rare Dis. 2023; 18(1):13.

PMID: 36650582 PMC: 9843874. DOI: 10.1186/s13023-022-02578-1.

References

Gonzalez-Cuyar L, Hunter B, Harris P, Perry G, Smith M, Castellani R . Cerebrotendinous xanthomatosis: case report with evidence of oxidative stress. Redox Rep. 2007; 12(3):119-24. DOI: 10.1179/135100007X200173. View

Schreiner A, Hopen G, Skrede S . Cerebrotendinous xanthomatosis (cholestanolosis). Investigations on two sisters and their family. Acta Neurol Scand. 1975; 51(5):405-16. View

Stahl W, SUMI S, Swanson P . Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis. J Neurochem. 1971; 18(3):403-13. DOI: 10.1111/j.1471-4159.1971.tb11968.x. View

Price Evans D, Salah K, Mobrad M, Mitchell W, Olin M, Eggertsen G . Cerebrotendinous xanthomatosis in a Saudi Arabian family-genotyping and long-term follow-up. Saudi Med J. 2007; 28(7):1113-8. View

Berginer V, Gross B, Morad K, Kfir N, Morkos S, Aaref S . Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics. 2009; 123(1):143-7. DOI: 10.1542/peds.2008-0192. View

Soffer D, Benharroch D, Berginer V . The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature. Acta Neuropathol. 1995; 90(2):213-20. DOI: 10.1007/BF00294324. View

Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, KUNNEN M . MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol. 2000; 10(4):576-8. DOI: 10.1007/s003300050964. View

Mignarri A, Dotti M, Puppo M, Gallus G, Giorgio A, Cerase A . Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up. Neuroradiology. 2012; 54(6):649-51. DOI: 10.1007/s00234-012-1026-8. View

MENKES J, Schimschock J, Swanson P . Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol. 1968; 19(1):47-53. DOI: 10.1001/archneur.1968.00480010065004. View

10.

Gaikwad S, Garg A, Mishra N, Gupta V, Srivastava A, Sarkar C . Cerebrotendinous xanthomatosis: neuroimaging findings in two siblings from an Indian family. Neurol India. 2003; 51(3):401-3. View

11.

Katz D, Scheinberg L, Horoupian D, Salen G . Peripheral neuropathy in cerebrotendinous xanthomatosis. Arch Neurol. 1985; 42(10):1008-10. DOI: 10.1001/archneur.1985.04060090090022. View

12.

Agrawal N, Garg S . Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation. BMJ Case Rep. 2012; 2012. PMC: 4543233. DOI: 10.1136/bcr-2012-006202. View

13.

Pudhiavan A, Agrawal A, Chaudhari S, Shukla A . Cerebrotendinous xanthomatosis--the spectrum of imaging findings. J Radiol Case Rep. 2013; 7(4):1-9. PMC: 3661428. DOI: 10.3941/jrcr.v7i4.1338. View

14.

Posada I, Ramos A . Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord. 2011; 17(7):570-2. DOI: 10.1016/j.parkreldis.2011.04.006. View

15.

Huang L, Miao X, Yang D, Tao H . Bilateral Achilles tendon enlargement. Orthopedics. 2011; 34(12):e960-4. DOI: 10.3928/01477447-20111021-28. View

16.

Mandrile G, Gallus G, Mura G, Di Sapio A, Sotgiu M, Montella A . Cerebrotendinous xanthomatosis: recurrence of the CYP27A1 mutation p.Arg479Cys in Sardinia. Neurol Sci. 2014; 35(8):1303-5. DOI: 10.1007/s10072-014-1696-6. View

17.

Nozue T, Higashikata T, Inazu A, Kawashiri M, Nohara A, Kobayashi J . Identification of a novel missense mutation in the sterol 27-hydroxylase gene in two Japanese patients with cerebrotendinous xanthomatosis. Intern Med. 2010; 49(12):1127-31. DOI: 10.2169/internalmedicine.49.3277. View

18.

Pedroso J, Pinto W, Souza P, Santos L, Abud I, Avelino M . Early-onset epilepsy as the main neurological manifestation of cerebrotendinous xanthomatosis. Epilepsy Behav. 2012; 24(3):380-1. DOI: 10.1016/j.yebeh.2012.04.121. View

19.

Chang W, Kuriyama M, Lui C, Jeng S, Chen W, Chee E . Cerebrotendinous xanthomatosis in three siblings from a Taiwanese family. J Formos Med Assoc. 1992; 91(12):1190-4. View

20.

Reichwaldt I, Zustin J, Wenke K, Ridderbusch I . Differential diagnosis of tendon tumors: xanthomas caused by hyperlipidemia in children. J Pediatr Surg. 2010; 45(10):e9-12. DOI: 10.1016/j.jpedsurg.2010.06.030. View